BioWorld

Dec. 23, 2008

Two Aussie Biotechs Merging to Focus on Phase III HIV Dru

Australian biotech firms Progen Pharmaceuticals Ltd. and Avexa Ltd. have agreed to merge, creating a new company with a well-funded oncology and HIV pipeline. (BioWorld Today) Read More

Obama Reveals Top Science Advisers and NOAA Chief

NPS Launches Pivotal Study of NPSP558 in Hypoparathyroidism

Amgen Files BLA for Denosumab in Bone Loss; No Partners (Yet?)

Other News To Note

Appointments And Advancements

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 10, 2025.

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

The Nasdaq Stock Exchange headquarters in New York

Omada, Caris arrivals continue med-tech IPO hot streak

BioWorld MedTech

Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...